Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
NASDAQ:VKTX
VKTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.92 - $81.73
Previous CloseN/A
Volume7.75M
Average Volume (3M)4.44M
Market Cap
$3.19B
Enterprise Value$3.06B
Total Cash (Recent Filing)$851.86M
Total Debt (Recent Filing)$1.00M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Jul 23, 2025EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding112,309,550
10 Day Avg. Volume3,218,922
30 Day Avg. Volume4,438,749
Financial Highlights & Ratios
PEG Ratio1.61
Price to Book (P/B)3.65
Price to Sales (P/S)0.00
P/FCF Ratio-23.09
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue3.51K
Enterprise Value/Gross Profit-18.87K
Enterprise Value/Ebitda-5.26
Forecast
1Y Price Target
$88.47Price Target Upside221.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Efficacy And Market PotentialVK2735 is considered incrementally better than tirzepatide, offering improved potency and pharmacokinetics, which could enhance its market potential.
Financial ResourcesViking Therapeutics has a strong cash position of $852M, which is expected to be sufficient to fund its Phase 3 study for injectable VK2735 and the Phase 2 oral study.
Market ShareFor general obesity, VK2735 is expected to take meaningful market share by being more effective than current treatments.
Trial ProgressThe Phase 2 study for the oral VK2735 is fully enrolled, indicating high interest in GLP-1 related therapies and a competitive edge for Viking Therapeutics.
Bears Say
Market CompetitionThe company's dual amylin and calcitonin program is advancing, and there is ongoing exploration for partnerships in other therapeutic areas, signaling competitive pressure.
Mergers And AcquisitionsThere is a perception that the supply agreement with CordenPharma reduces the likelihood of near-term mergers and acquisitions.
---
Ownership Overview
2.78% Insiders
25.34% Mutual Funds
11.03% Other Institutional Investors
47.29% Public Companies and Individual Investors
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $18.92 and its highest was $81.73 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.19B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Jul 23, 2025 which is in 64 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Apr 23, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.328 by -$0.082.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -0.45.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 112,309,550 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.328. Following the earnings report the stock price went down -0.504%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in VKTX
---
Viking Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.47 (221.71% Upside)
$88.47 (221.71% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 75.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $29.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.83%
12-Months-Change
Fundamentals
Return on Equity
-14.40%
Trailing 12-Months
Asset Growth
-10.39%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
---
VKTX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong focus on successful clinical trial results and a solid financial position, despite increased expenses and net loss. The company is advancing its lead programs with significant progress in pipeline development.Read More>---
VKTX Stock 12 Month Forecast
Average Price Target
$88.47
▲(221.71% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Immunovant
―
---